Latest Developments on Ebola, Hepatitis B, and Long Covid

Key Takeaways

• CDC and WHO report Bundibugyo Ebola outbreaks; ERVEBO is not expected to protect against Bundibugyo virus.
• GSK’s bepirovirsen has a FDA PDUFA goal date of October 26, 2026 after priority-review acceptance.
• NIH-supported REVERSE-LC (NCT06631287) is recruiting to test baricitinib for neurologic and cardiopulmonary long COVID symptoms.
• No FDA-approved Bundibugyo-specific vaccine or therapy exists; countermeasures belong in trials.

What is new on Ebola that pharma teams must track?

CDC issued a Health Alert Network advisory on Ebola disease in the Democratic Republic of the Congo and Uganda caused by Bundibugyo virus. The advisory states there is currently no FDA-licensed or authorized vaccine to protect against Bundibugyo virus infection, and that ERVEBO is indicated for Orthoebolavirus zairense only. See the CDC HAN notice.

WHO convened experts who advised that candidate Bundibugyo vaccines and therapeutics should be used inside clinical trials to generate robust data. WHO also cautioned against using licensed Zaire Ebola vaccines outside carefully designed research settings for Bundibugyo disease. The May 28, 2026 WHO update is the primary framing for R&D partners.

Africa regional WHO pages describe a Public Health Emergency of International Concern declaration tied to the outbreak response. Companies with filovirus platforms should prioritize trial-ready stock, cold-chain logistics, and ethics packages rather than promotional claims about cross-protection.

WHO later noted patient enrolment opening in the PARTNERS treatment trial for Bundibugyo virus disease, underscoring that efficacy still must be proven prospectively before any commercial narrative forms.

Where does the hepatitis B functional-cure pipeline stand?

GSK’s bepirovirsen NDA is under FDA priority review with a October 26, 2026 PDUFA goal date and Breakthrough Therapy designation, per GSK’s announcement. Supporting Phase 3 studies include B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820).

Functional cure, as defined in company materials, requires sustained HBsAg undetectability after stopping therapy. That endpoint is commercially meaningful because lifelong nucleoside analogues dominate today’s market. Until labeling exists, payers will demand clarity on who benefits most—especially patients with lower baseline HBsAg.

Competitive intelligence teams should also watch how any U.S. label interacts with European and Japanese reviews that GSK has said are underway, without assuming synchronized launch dates across regions.

What long COVID trials are actually enrolling?

The REVERSE-LC trial (NCT06631287) is a Phase 3 randomized, double-blind, placebo-controlled study of baricitinib versus placebo for persistent neurologic and cardiopulmonary symptoms of long COVID. Registry details list an enrollment target around 550 participants, with NIH and National Institute on Aging funding noted on the record.

NIH’s broader RECOVER-Treating Long COVID effort has also discussed additional protocols, including low-dose naltrexone and GLP-1 approaches, but baricitinib is the clearest late-stage interventional signal with a public NCT identifier and active recruiting status. Teams should not market off-label COVID-19 or long COVID uses of JAK inhibitors without regulatory authorization.

How should portfolio strategy connect these three files?

Ebola work is outbreak-gated and primarily public-sector financed. Hepatitis B is a classic specialty-launch problem with a dated FDA clock. Long COVID is a heterogeneous syndrome where endpoint selection and biomarker strategy will decide whether Phase 3 wins translate into labels. Capital committees should keep outbreak MCM, antiviral specialty, and post-viral immunology budgets separate even when news cycles bundle them.

For medical affairs, the shared communications rule is simple: cite CDC, WHO, ClinicalTrials.gov, and sponsor releases—and distinguish licensed products from candidates in every HCP-facing deck.

Across all three files, procurement calendars should separate outbreak MCM budgeting, specialty hepatology launch readiness for late 2026, and long COVID trial readout planning into 2027 so headline bundling does not distort go-to-market sequencing.

What remains unproven?

Bundibugyo vaccine and monoclonal efficacy in humans is not established. Bepirovirsen’s U.S. label text is unknown until FDA action. Baricitinib’s benefit for long COVID cognition and cardiopulmonary outcomes is still being tested; approved JAK-inhibitor indications do not automatically extend to long COVID.

Related NovaPharma coverage

• Ebola outbreak implications for women and girls
• Hepcludex FDA approval for hepatitis D
• Ebola 2026 U.S. response and travel debate

How should evidence teams document claims?

Keep a living evidence log that maps each numeric claim to a dated primary URL, captures the exact denominator, and notes whether the figure is intent-to-treat, per-protocol, or sponsor-described. When a press release and a peer-reviewed abstract diverge, privilege the peer-reviewed or labeling source and delete the weaker claim from customer-facing copy.

Internal reviewers should reject any draft that cites competitor newsrooms as hyperlinks, invents savings percentages, or treats a PDUFA goal date as an approval. Those process rules protect YMYL credibility as much as the underlying science does for readers making clinical or capital decisions.

Quarterly refresh cycles should re-check every outbound allowlisted link for link rot and replace dead URLs before republication so citation integrity survives beyond the first audit pass.

Frequently Asked Questions

Primary Sources

1. CDC HAN: Bundibugyo Ebola outbreak advisory
2. WHO: Bundibugyo vaccine and treatment advice
3. GSK: bepirovirsen FDA priority review
4. ClinicalTrials.gov: REVERSE-LC NCT06631287